Atea Pharmaceuticals Inc (AVIR)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Atea Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 4.70 $ — 56% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
Uses AIAtea Pharmaceuticals ist ein Antiviren-Biotech (HCV-Kandidat) ohne jede KI-Umsatzquelle; im 10-K FY2025 und im 10-Q Q1/2026 erklärt Atea aber ausdrücklich und wiederholt, den eigenen KI-Einsatz auszuweiten („We are increasing our use of AI tools and technology throughout our business“) — flankiert von Risiko-Passagen zu KI-Regulierung und einem möglichen Wettbewerbsnachteil, falls Konkurrenten KI in der Wirkstoffsuche besser nutzen. Das ist belegter operativer KI-Einsatz, kein konkretes Bedrohungs-Szenario fürs Geschäftsmodell; die drei älteren 10-Qs und das 10-K FY2024 sind komplett ohne KI-Erwähnung.
View the full file — quotes, sources, reviewed filings
„Our business may be affected by the evolving regulatory framework relating to the use of AI. We are increasing our use of AI tools and technology throughout our business. The regulatory framework for AI is rapidly evolving as many federal, state, and foreign government bodies and agencies have introduced or are currently considering additional laws and regulations."
Unser Geschäft könnte durch den sich entwickelnden Rechtsrahmen für den Einsatz von KI beeinträchtigt werden. Wir weiten den Einsatz von KI-Werkzeugen und -Technologien in unserem gesamten Geschäftsbetrieb aus. Der Rechtsrahmen für KI entwickelt sich rasant, da viele Regierungsstellen und Behörden auf Bundes-, Bundesstaats- und ausländischer Ebene zusätzliche Gesetze und Vorschriften eingebracht haben oder derzeit erwägen.
„In the biopharmaceutical industry, AI is being increasingly used by companies and entities with which we compete. We are increasing our use of AI but other entities may be more advanced in their deployment and use of AI which may enhance such other entities’ business operations particularly their discovery efforts and the integration of operational efficiencies in the preclinical and clinical development of product candidates. If we are unable to use AI as effectively as our competitors, we could experience competitive disadvantages."
In der biopharmazeutischen Industrie wird KI zunehmend von Unternehmen und Einrichtungen eingesetzt, mit denen wir im Wettbewerb stehen. Wir weiten unseren KI-Einsatz aus, aber andere Akteure könnten bei der Einführung und Nutzung von KI weiter fortgeschritten sein, was deren Geschäftsbetrieb stärken könnte — insbesondere ihre Wirkstoffsuche und die Integration betrieblicher Effizienzgewinne in der präklinischen und klinischen Entwicklung von Produktkandidaten. Wenn wir KI nicht so wirksam einsetzen können wie unsere Wettbewerber, könnten wir Wettbewerbsnachteile erleiden.
„We are increasing our use of AI tools and technology throughout our business."
Wir weiten den Einsatz von KI-Werkzeugen und -Technologien in unserem gesamten Geschäftsbetrieb aus.
Filings Reviewed: 10-Q 2026-05-12 · 10-Q 2025-11-12 · 10-Q 2025-08-07 · 10-Q 2025-05-12 · 10-K 2026-03-05 · 10-K 2025-03-06
Rated on July 8, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 84.5% above the current price.
- Consensus
- Hold
- Analyst Ratings
- 3
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.93 | -2.20 – -1.65 | 0 | 0.8% | 2 |
| 12/31/2027 | -1.39 | -1.65 – -1.12 | 30 | 28.1% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.56 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.40 | – | 0 | – | -8,063.20 | -30 | -30 |
| 2025: Q1 | -0.40 | – | 0 | – | – | -31 | -31 |
| 2025: Q2 | -0.44 | – | 0 | – | – | -33 | -33 |
| 2025: Q3 | -0.53 | – | 0 | – | – | -40 | -40 |
| 2025: Q4 | -0.57 | – | 0 | -100.00 | – | -28 | -28 |
| 2026: Q1 | -0.57 | – | 0 | – | – | -46 | -46 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 0 | -9 | -9 | -0.90 | -8 | -36 | 35 |
| 2019 | 0 | -15 | -13 | -0.16 | -13 | -50 | 22 |
| 2020 | 49 | -11 | -11 | -0.13 | 297 | 548 | 864 |
| 2021 | 351 | 138 | 121 | 1.37 | -87 | 710 | 773 |
| 2022 | 192 | -131 | -116 | -1.39 | -121 | 641 | 667 |
| 2023 | 0 | -164 | -136 | -1.63 | -85 | 555 | 595 |
| 2024 | 0 | -193 | -168 | -2.00 | -136 | 439 | 465 |
| 2025 | 0 | -181 | -158 | -1.94 | -132 | 275 | 315 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
| Employees | 55 |
|---|---|
| Headquarters | Boston, MA |
| Address | 225 Franklin Street, 02110 Boston, United States |
| Phone | 857 284 8891 |
| Website | ateapharma.com |
| IPO Date | 30. Oct 2020 |
| ISIN | US04683R1068 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jean-Pierre Sommadossi Ph.D. | Founder, Chairman, CEO & President | 1956 |
| Andrea J. Corcoran J.D. | CFO, Executive VP of Legal & Secretary | 1962 |
| John F. Vavricka | Chief Commercial Officer | 1963 |
| Janet M. J. Hammond M.D., Ph.D. | Chief Development Officer | 1960 |
| Maria Arantxa Horga M.D. | Chief Medical Officer | 1968 |
| Wayne Foster CPA | Executive VP of Finance & Chief Accounting Officer | 1969 |
| Jonae R. Barnes | Senior Vice President of Investor Relations & Corporate Communications | – |
| Adel Moussa Ph.D. | Executive Vice President of Chemistry | – |
| Xiao-Jian Zhou Ph.D. | Executive Vice President of Early Stage Development | – |
| Keith Pietropaolo | Executive VP of Clinical Sciences & Project Management | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.